门窦血管病诊疗研究进展

doi:10.3870/j.issn.1672-8009.2026.05.014

医学分子生物学杂志 ›› 2026, Vol. 23 ›› Issue (5): 587-591.doi: 10.3870/j.issn.1672-8009.2026.05.014

门窦血管病诊疗研究进展

边昊¹, 魏红山^1,2

¹首都医科大学附属北京地坛医院消化内科北京市, 100015;
²首都医科大学HBV感染、临床治愈与免疫联合实验室北京市, 100015

收稿日期:2026-04-16 出版日期:2026-09-30 发布日期:2026-09-30
通讯作者: 魏红山（E-mail：drwei@ccmu.edu.cn）
基金资助:
首医HBV感染、临床治愈和免疫联合实验室（No.JL202508）,首都卫生发展科研专项重点项目子课题（No.首发2024-1-4081）

Advances in Diagnosis and Management of Porto-Sinusoidal Vascular Disease

BIAN Hao¹, WEI Hongshan^1,2

¹Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China;
²HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100015, China

Received:2026-04-16 Online:2026-09-30 Published:2026-09-30
Contact: WEI Hongshan （E-mail：drwei@ccmu.edu.cn）
Supported by:
HBV Infection, Clinical Cure and Immunotherapy Joint Laboratory of Capital Medical University（No.JL202508） and the Key Program Subproject of the Capital Health Research and Development Special Fund（No.2024-1-4081）

摘要/Abstract

摘要： 门窦血管病（porto-sinusoidal vascular disease,PSVD）是近年来新界定的肝脏血管性疾病,其特征为门脉-窦性微循环结构损伤及由此引起的门静脉高压相关并发症。随着病理学、转录组学与遗传学研究以及医学影像技术的发展,针对PSVD 的诊断识别已由单纯临床排除性诊断进展为采用病理学、分子生物学和无创检查等多种手段进行综合评估的精准诊疗模式。文章围绕 PSVD 的病理生理学与分子机制、病理学基础、临床表现、分子与无创诊断线索及治疗策略等方面进行综述,并对分层诊断模型与机制导向治疗的研究方向进行展望。

关键词: 门窦血管病, 门静脉高压, 分子机制, 分子标志物

Abstract: Porto-sinusoidal vascular disease （PSVD） is a recently redefined vascular liver disorder characterized by structural injury of the porto-sinusoidal microcirculation and consequent complications related to portal hypertension. With advances in histopathology, transcriptomics, genetic studies, and medical imaging technologies, the diagnostic approach to PSVD has evolved from a primarily exclusion-based clinical diagnosis toward a precision-oriented strategy integrating pathological assessment, molecular profiling, and non-invasive evaluation. This review summarizes recent progress in the pathophysiological and molecular mechanisms, histopathological features, clinical manifestations, molecular and non-invasive diagnostic clues, and therapeutic strategies of PSVD. Furthermore, we discuss future perspectives regarding the development of stratified diagnostic models and mechanism-directed therapeutic approaches for this disease.

Key words: porto-sinusoidal vascular disease, portal hypertension, molecular mechanisms, biomarkers

中图分类号:

R575.2

边昊, 魏红山. 门窦血管病诊疗研究进展[J]. 医学分子生物学杂志, 2026, 23(5): 587-591.

BIAN Hao, WEI Hongshan. Advances in Diagnosis and Management of Porto-Sinusoidal Vascular Disease[J]. Journal of Medical Molecular Biology, 2026, 23(5): 587-591.

参考文献

[1] DE GOTTARDI A,RAUTOU P E,SCHOUTEN J,et al.Porto-sinusoidal vascular disease: Proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol,2019,4(5):399-411.
[2] DE GOTTARDI A,SEMPOUX C,BERZIGOTTI A.Porto-sinusoidal vascular disorder[J]. J Hepatol,2022,77(4):1124-1135.
[3] DE FRANCHIS R,BOSCH J,GARCIA-TSAO G,et al.Baveno VII-Renewing consensus in portal hypertension[J]. J Hepatol,2022,76(4):959-974.
[4] TÉLLEZ L,DONATE J,ALBILLOS A. Portosinusoidal vascular disorder: A paradigm shift[J]. Med Clin,2024,162(9):439-447.
[5] PREMKUMAR M,ANAND A C.Porto-sinusoidal vascular disease: Classification and clinical relevance[J]. J Clin Exp Hepatol,2024,14(5):101396.
[6] ZHANG Y,XIONG Q,ZHONG Y,et al.Clinical characteristics and natural history of Porto-sinusoidal vascular disease: A cohort study of 234 patients in China[J]. Liver Int,2024,44(9):2329-2340.
[7] MAGAZ M,GIUDICELLI-LETT H,ABRALDES J G,et al.Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome[J]. J Hepatol,2025,82(1):72-83.
[8] HERNÁNDEZ-GEA V,CAMPRECIÓS G,BETANCOURT F,et al. Co-expression gene network analysis reveals novel regulatory pathways involved in Porto-sinusoidal vascular disease[J]. J Hepatol,2021,75(4):924-934.
[9] CERDA REYES E,GONZÁLEZ-NAVARRO E A,MAGAZ M,et al. Autoimmune biomarkers in Porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology[J]. Liver Int,2021,41(9):2171-2178.
[10] TONUTTI A,PUGLIESE N,CERIBELLI A,et al.The autoimmune landscape of Porto-sinusoidal vascular disorder: What the rheumatologist needs to know[J]. Semin Arthritis Rheumatism,2024,67:152467.
[11] GIOIA S,CARNEVALE R,TAVANO D,et al.Association between gut-derived endotoxins and Porto-sinusoidal vascular disorder with portal hypertension[J]. Aliment Pharmacol Ther,2023,58(11-12):1205-1216.
[12] OVERI D,PUGLIESE N,CARNEVALE R,et al.Role of Gut-Derived Endotoxins in Porto-Sinusoidal Vascular Disorder: Comparison Between patients with and without portal hypertension[J]. Liver Int,2025,45(9):e70277.
[13] SHAN J,MEGARBANE A,CHOUCHANE A,et al.Genetic predisposition to Porto-sinusoidal vascular disorder: A functional genomic-based,multigenerational family study[J]. Hepatology,2022,77(2):501-511.
[14] CIRIACI N,BERTIN L,RAUTOU P E.Genetic predisposition to Porto-sinusoidal vascular disorder[J]. Hepatology,2026,83(2):409-424.
[15] COUKOS A,SAGLIETTI C,SEMPOUX C,et al.High prevalence of short telomeres in idiopathic Porto-sinusoidal vascular disorder[J]. Hepatol Commun,2024,8(8):e0500.
[16] OLIVAS P,PEREZ-CAMPUZANO V,ORTS L,et al.Porto-sinusoidal vascular disorder in chronic HBV: A significant coexistence not to be overlooked[J]. JHEP Rep,2024,6(3):100996.
[17] PUENTE A,FORTEA J I,DEL POZO C,et al.Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure[J]. Dig Liver Dis,2024,56(10):1721-1729.
[18] RUBBIA-BRANDT L,TAUZIN S,BREZAULT C,et al.Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans[J]. Mol Cancer Ther,2011,10(4):687-696.
[19] KMEID M,LIU X,BALLENTINE S,et al.Idiopathic non-cirrhotic portal hypertension and Porto-sinusoidal vascular disease: Review of current data[J]. Gastroenterology Res,2021,14(2):49-65.
[20] BURT A D,GOUW A S H,CALLEA F,et al. Making sense of ‘Porto-sinusoidal vascular disorder’: What does it mean for the pathologist and the patient?[J]. Liver Int,2025,45(1):e16196.
[21] 董思晗,赵新颜. 门静脉肝窦血管病临床病理特征及研究进展[J]. 中国中西医结合消化杂志,2024,32(12):1051-1055.
DONG S H,ZHAO X Y.Clinicopathological features and new advancement of Porto-sinusoidal vascular disease[J]. Chin J Integr Tradit West Med Dig,2024,32(12):1051-1055.
[22] GIULI L,PALLOZZI M,VENTURINI G,et al.Molecular mechanisms underlying vascular liver diseases: Focus on thrombosis[J]. Int J Mol Sci,2023,24(16):12754.
[23] DE BROUCKER C,PARADIS V,BOTERO M L,et al.Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of Porto-sinusoidal vascular disorder[J]. JHEP Rep,2026,8(1):101670.
[24] WÖRAN K,SEMMLER G,JACHS M,et al. Clinical course of Porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol,2022,20(2):e251-e266.
[25] HE Y,LIU H,LIU Y,et al.Clinical characteristics and outcomes of portal vein thrombosis in patients with Porto-sinusoidal vascular disease: A cohort study[J]. J Clin Transl Hepatol,2025,13(10):825-834.
[26] PUGLIESE N,GIULI L,MASTROROCCO E,et al.Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease-A comprehensive narrative review[J]. Dig Liver Dis,2024,56(6):964-970.
[27] HERCUN J,ASIF B,VITTAL A,et al.Development of hepatic fibrosis in common variable immunodeficiency-related Porto-sinusoidal vascular disorder[J]. Aliment Pharmacol Ther,2024,60(7):888-896.
[28] BAUMERT L S,SHIH A,CHUNG R T.Management of liver disease and portal hypertension in common variable immunodeficiency (CVID)[J]. JHEP Rep,2023,5(11):100882.
[29] ZHANG Y,LIU H,XIONG Q,et al.Application of liver biopsy in etiological diagnosis of unexplained portal hypertension: Porto-sinusoidal vascular disease should not be ignored[J]. Medicine,2024,103(39):e39819.
[30] SEMMLER G,PETRENKO O,LOZANO J J,et al.Metabolomic profiles differentiate between Porto-sinusoidal vascular disorder,cirrhosis,and healthy individuals[J]. JHEP Rep,2024,6(12):101208.
[31] PUGLIESE N,PONZIANI F R,CERINI F,et al.Link between persistent,unexplained gamma-glutamyltransferase elevation and Porto-sinusoidal vascular disorder[J]. JHEP Rep,2024,6(9):101150.
[32] VALAINATHAN S R,SARTORIS R,ELKRIEF L,et al.Contrast-enhanced CT and liver surface nodularity for the diagnosis of Porto-sinusoidal vascular disorder: A case-control study[J]. Hepatology,2022,76(2):418-428.
[33] LAMPICHLER K,SEMMLER G,WÖRAN K,et al. Imaging features facilitate diagnosis of Porto-sinusoidal vascular disorder[J]. Eur Radiol,2023,33(2):1422-1432.
[34] 刘建建,张芝,黄晶晶,等. 肝门静脉肝血窦疾病的影像学诊断研究进展[J]. 中国中西医结合消化杂志,2024,32(12):1056-1059.
LIU J J,ZHANG Z,HUANG J J,et al.Advances in the imanging diagnosis of Porto-sinusoidal vascular disease[J]. Chin J Integr Tradit West Med Dig,2024,32(12):1056-1059.
[35] ZHANG G,MA L,FU L,et al.Diagnostic performance of transient elastography in differentiation between Porto-sinusoidal vascular liver disease and compensated cirrhosis[J]. Liver Int,2023,43(11):2513-2522.
[36] MOGA L,PARADIS V,FERREIRA-SILVA J,et al.Performance of spleen stiffness measurement to rule out high-risk varices in patients with Porto-sinusoidal vascular disorder[J]. Hepatology,2025,81(2):546-559.
[37] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: Vascular diseases of the liver[J]. J Hepatol,2016,64(1):179-202.
[38] MIRONOVA M,GOPALAKRISHNA H,KOH C,et al.Portal sinusoidal vascular diseases: Assessment and therapy[J]. Hepatology,2025. DOI: 10.1097/HEP.0000000000001344
[39] BISSONNETTE J,GARCIA-PAGÁN J C,ALBILLOS A,et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension[J]. Hepatology,2016,64(1):224-231.
[40] KNITTER S,DUWE G,BEIERLE A S,et al.Inhibition of vascular endothelial growth factor protects against the development of oxaliplatin-induced sinusoidal obstruction syndrome in wild-type but not in CD39-null mice[J]. Cancers,2022,14(23):5992.

门窦血管病诊疗研究进展

Advances in Diagnosis and Management of Porto-Sinusoidal Vascular Disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价